Several pre-clinical studies and clinical trials have demonstrated that FGFR2 rearrangements in cholangiocarcinoma can predict tumor sensitivity to FGFR2 inhibitors and become an important therapy in these highly selected patients [27–29]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.